Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Vaxart entered a contract modification with BARDA reducing total available funding to approximately $345 million, a decrease of $116 million reflecting a 50% reduction in trial participants ordered last year. The modification releases $29 million to fund completion of the Phase 2b COVID-19 oral pill vaccine trial and exploratory analyses. The company intends to report 12-month data from the 400-participant Sentinel Cohort in the coming weeks, with 12-month data from the 5,085-participant main cohort expected in the first half of 2027.
Key figures
- Total funding
- $345 million
- Funding decrease
- $116 million
- Main cohort size
- 5085
- New release funding
- $29 million
- Sentinel cohort size
- 400
- Participant reduction
- 50%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.